Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2006-04-04
2006-04-04
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S255050, C514S256000, C514S026000, C514S269000, C514S272000, C514S274000, C514S275000, C544S265000, C544S266000, C544S268000, C544S276000, C544S277000, C544S301000, C544S311000, C544S312000, C544S316000, C544S317000, C544S319000, C544S320000, C544S322000, C544S323000, C544S329000, C544S332000, C544S334000, C544S335000, C544S336000, C544S408000, C544S409000, C546S077000
Reissue Patent
active
RE039056
ABSTRACT:
Compounds of structural Formula (I)and pharmacologically acceptable salts and esters thereof possess 5α-reductase inhibitory activity. These compounds inhibit 5α-reductase type 1 and type 2. The compounds of structural Formula I are useful in the systemic, including oral, and parenteral, including topical, treatment and prevention of hyperandrogenic conditions including prostatic carcinoma, benign prostatic hyperplasia, acne vulgaris, seborrhea, androgenic alopecia (also called androgenetic alopecia) which includes male- and female-pattern baldness, female hirsutism, and prostatitis. A class of compounds of the present invention are also potent antiandrogens. The present invention also relates to novel compositions containing such compounds, methods of their use and methods of their manufacture.
REFERENCES:
patent: 4191759 (1980-03-01), Johnston
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 5084574 (1992-01-01), Bhattacharya et al.
patent: 5116983 (1992-05-01), Bhattacharya
patent: 5151429 (1992-09-01), Rasmusson
patent: 5302621 (1994-04-01), Kojima et al.
patent: 5304562 (1994-04-01), Biollaz
patent: 5547957 (1996-08-01), Gormley et al.
patent: 5565467 (1996-10-01), Batchelor et al.
patent: 5693809 (1997-12-01), Durette et al.
patent: 5693810 (1997-12-01), Rasmusson et al.
patent: 5696266 (1997-12-01), Humphrey et al.
patent: 5817802 (1998-10-01), Humphrey et al.
patent: 5872126 (1999-02-01), Cukierski et al.
patent: 5998427 (1999-12-01), Batchelor et al.
patent: 6121449 (2000-09-01), Panzeri et al.
patent: 6645974 (2003-11-01), Hutchinson et al.
patent: 0 004 949 (1979-04-01), None
patent: 0 004 949 (1979-04-01), None
patent: 0 655 459 (1990-11-01), None
patent: 0 484 094 (1992-06-01), None
patent: 0 538 192 (1993-04-01), None
patent: WO 92/16213 (1992-10-01), None
patent: WO 94/07861 (1994-04-01), None
patent: WO 94/11385 (1994-05-01), None
patent: WO 94/15602 (1994-07-01), None
patent: WO 95/07926 (1995-03-01), None
patent: WO 95/07927 (1995-03-01), None
patent: WO 97/11702 (1997-04-01), None
Bakshi, R.K., et al., 4-aza-3-oxo-5a-androst-1-ene-17b-N-aryl-carboxamides as dual inhibitors of human type 1 and type 2 steroid 5a-reductases. J. Med. Chem. 38 (1995), pp. 3189-3192.
Tolman et al., “4-Methyl-3-oxo-4-aza-5alpha-androst-1-en17beta-N-aryl-carboxamides: An approach to combined androgen blockage”; Mar. 1997 issue of J. Steroid Biochem & Molec. Bio. vol. 60, No. 5-6 pp. 303-309.
Andriole et al., “Treatment with Finasteride Following Radical Prostatectormy for Prostate Cancer”, Urology 45(3): 491-497 (1995).
Tsukamoto et al., “Chemoprevention of Rat Prostate Carcinogenesis by Use of Finasteride or Casodex”, 87 J. Nat'l Cancer Inst., pp. 842-843 (1995).
Tolman et al., 5th Int'l Congress Hormones & Cancer Program and Abstract, Quebec City, Sep. 16-20, 1995, p. 92, Abstract 48, 4-methyl-4-azateroid 17beta(N-aryl substituted)carboxamides: Potent antiandrogenic activity with 5a-reductase inhibition.
Bologna et al, “Antiandrogens and 5-alpha Reductase Inhibition of the Proliferation Rate in PC3 and DU145 Human Prostatic Cancer Cell Lines”, 51(6) Curr. Ther. Res., pp. 799-813 (1992).
Denis, Commentary on maximal androgen blockade in prostate cancer: A theory to put into practice. Prostate 27 (1995), pp. 223-240.
Bakshi et al., ACS Division of Medicinal Chemistry, 209th ACS Nat'l meeting Anaheim, CA, Apr. 2-6, 1995, Abstract No. 011, N-Phenyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamides as inhibitors of both human type 1 and type 2 5alpha-redutases.
Rasmusson et al., J. Med. Chem., vol. 29, pp. 2298-2315 (1986), “Azasteroids: Structure-activity relationships for inhibition of 5alpha-reductase and of androgen receptor binding.”
Liang et al., Endrocrinology, vol. 117, pp. 571-579 (1985), “Species differences in prostatic steroid 5alpha-reductases of rat, dog, and human”.
Bakshi, R.K., et al., “4-Aza-3-oxo-5a-androst-1-ene-17b-N-aryl-carboxamides as Dual Inhibitors of Human Type 1 and Type 2 Steroid 5a-Reductases. Dramatic Effect of N-Aryl Substituents on Type 1 and Type 2 5a-Reductase Inhibitory Potency.”, J. Med. Chem., vol. 38, No. 17, 1995.
Bakshi, et al., Additions and Corrections, J. of Med. Chem., vol. 39, No. 5, p. 1192, 1996.
Mellin, T.N., et al., “Azateroids as Inhibitors of Testosterone 5a-Reductase In Mammalian Skin”, J. of Steroid Biochem. and Molec. Bio., vol. 44, No. 2, pp. 121-131, 1993.
Rasmusson, G.H., et al., “Azasteroids as Inhibitors of Rat Prostatic 5a-Reductase”, J. of Med. Chem., vol. 27, No. 12, pp. 1690-1701, 1984.
Zheng, Jinhong, et al., Chem. Abs., vol. 122, No. 25, 1995.
Kurata, H., et al., “Synthesis and Testosterone 5a-Reductase-Inhibitory Activity of 4-Aza-5a-androstane-17-caboxamide Compound with an Aromatic Moiety in the C-17 Carbamoyl Group”, Chem. Pharm. Bull. vol. 44(1), pp. 115-121 (1996).
Bakshi Raman K.
Sahoo Soumya P.
Tolman Richard L.
Coleman Brenda
Daniel Mark R.
Merck & Co Inc.
Shatynski Patricia A.
LandOfFree
4-Azasteroids for treatment of hyperandrogenic conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-Azasteroids for treatment of hyperandrogenic conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-Azasteroids for treatment of hyperandrogenic conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3590212